Provided by Tiger Trade Technology Pte. Ltd.

CANSINOBIO

29.480
-2.580-8.05%
Volume:24.32M
Turnover:732.97M
Market Cap:7.28B
PE:268
High:31.980
Open:30.740
Low:28.080
Close:32.060
52wk High:56.550
52wk Low:19.220
Shares:247.04M
HK Float Shares:132.67M
Volume Ratio:2.75
T/O Rate:18.33%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.110
ROE:-0.02%
ROA:-0.83%
PB:1.27
PE(LYR):268.00
PS:5.57

Loading ...

AH Share Premium and Deviation Rankings as of July 13th Close

Stock News
·
Jul 13

CANSINOBIO Sees Stable Share Capital in June 2026; Public Float Meets HKEX Requirement

Bulletin Express
·
Jul 03

AH Share Premium and Deviation Rankings for July 3rd

Stock News
·
Jul 03

CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Argentina

MT Newswires Live
·
Jun 25

CanSino Biologics: MCV4 Vaccine Gains Argentine Registration, Advancing Global Strategy

Bulletin Express
·
Jun 25

CansinoBIO Secures Regulatory Approval in Argentina for Meningococcal Vaccine

Stock News
·
Jun 25

CanSino Biologics Defines Governance, Capital Structure and Dividend Policy in Updated Articles of Association

Bulletin Express
·
Jun 10

CANSINOBIO Keeps Share Capital Steady in May; 2.91 Million Shares Reserved for Incentive Plans

Bulletin Express
·
Jun 02

CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine

MT Newswires Live
·
May 26

CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled

Stock News
·
May 26

CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient

Bulletin Express
·
May 26

CANSINOBIO Sets 2025 AGM for 10 June 2026; Seeks Share-Issuance, Repurchase and Dividend Mandates

Bulletin Express
·
May 19

CANSINOBIO Calls 10 June 2026 AGM to Approve 2025 Results, No Dividend Payout, and Fresh Financing Mandates

Bulletin Express
·
May 19

CanSino Biologics' Drug Application for Combined Vaccines Granted Priority Review in China

MT Newswires Live
·
May 11

CansinoBIO's Td5cp Vaccine for Adolescents and Adults Granted Priority Review by China's Drug Regulator

Stock News
·
May 11

CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives

Simply Wall St.
·
Apr 30

UBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line

Stock News
·
Apr 30

CanSinoBIO Proposes Comprehensive Amendments to Articles and Board Procedures to Strengthen Governance

Bulletin Express
·
Apr 28

CANSINOBIO Reports Widened Net Loss in Q1

Stock News
·
Apr 28

康希诺生物2025年业绩扭亏为盈,核心疫苗销售推动营收突破10.59亿元

Bulletin Express
·
Apr 22